000141313 001__ 141313
000141313 005__ 20240229112524.0
000141313 0247_ $$2doi$$a10.1093/jnci/djy170
000141313 0247_ $$2pmid$$apmid:30388256
000141313 0247_ $$2ISSN$$a0027-8874
000141313 0247_ $$2ISSN$$a0198-0157
000141313 0247_ $$2ISSN$$a1460-2105
000141313 0247_ $$2altmetric$$aaltmetric:51038878
000141313 037__ $$aDKFZ-2018-01832
000141313 041__ $$aeng
000141313 082__ $$a610
000141313 1001_ $$0P:(DE-He78)6e02c183f41e45a5867dec393fb4616a$$aAmitay, Efrat$$b0$$eFirst author
000141313 245__ $$aAssociation of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes.
000141313 260__ $$aOxford$$bOxford Univ. Press$$c2019
000141313 3367_ $$2DRIVER$$aarticle
000141313 3367_ $$2DataCite$$aOutput Types/Journal article
000141313 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1681897442_17226
000141313 3367_ $$2BibTeX$$aARTICLE
000141313 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141313 3367_ $$00$$2EndNote$$aJournal Article
000141313 520__ $$aRegular use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) for a longer period has been inversely associated with colorectal cancer (CRC) risk. However, CRC is a heterogenic disease, and little is known regarding the associations with molecular pathological subtypes.Analyses included 2444 cases with a first diagnosis of CRC and 3130 healthy controls from a German population-based case control study. Tumor tissue samples were analyzed for major molecular pathological features: microsatellite instability (MSI), CpG island methylator phenotype, B-Raf proto-oncogene serine/threonine kinase (BRAF) mutation, and Kirsten rat sarcoma viral oncogene homolog gene (KRAS) mutation. Information on past and current use of NSAIDs, including aspirin, was obtained by standardized interviews. Multinomial logistic regression models were used to calculate adjusted odds ratios (ORs) and 95% confidence intervals (CIs). All statistical tests were two-sided.Regular use of NSAIDs was associated with a reduced CRC risk if tumors were MSS (OR = 0.66, 95% CI = 0.57 to 0.77), BRAF wildtype (OR = 0.67, 95% CI = 0.58 to 0.78), or KRAS wildtype (OR = 0.68, 95% CI = 0.58 to 0.80). Regular NSAID use was less clearly and mostly not statistically significantly associated with CRC risk reduction for MSI-high, BRAF-mutated, or KRAS-mutated CRC. In more specific analyses on MSI-high CRC, regular use of NSAIDs was associated with much stronger risk reduction in the absence of BRAF or KRAS mutations (OR = 0.34, 95% CI = 0.18 to 0.65) but not with KRAS- or BRAF-mutated MSI-high CRC (Pheterogeneity < .001). Results for just aspirin use were similar.Our study suggests variation in risk reduction of CRC subtypes following regular use of NSAIDs and aspirin. Regular use of NSAIDs and aspirin may be more strongly associated with risk reduction of MSI-high CRC without KRAS or BRAF mutation.
000141313 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000141313 588__ $$aDataset connected to CrossRef, PubMed,
000141313 7001_ $$0P:(DE-He78)7d7ee36ed0313bbc4c91bc3df5950107$$aCarr, Prudence$$b1
000141313 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b2
000141313 7001_ $$0P:(DE-He78)6c2a1ea8cce3580fe2d1c1df120a92b9$$aWalter, Viola$$b3
000141313 7001_ $$aRoth, Wilfried$$b4
000141313 7001_ $$aHerpel, Esther$$b5
000141313 7001_ $$0P:(DE-HGF)0$$aKloor, Matthias$$b6
000141313 7001_ $$0P:(DE-HGF)0$$aBläker, Hendrik$$b7
000141313 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b8
000141313 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b9
000141313 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b10$$eLast author
000141313 773__ $$0PERI:(DE-600)1465951-7$$a10.1093/jnci/djy170$$n5$$p475–483$$tJournal of the National Cancer Institute$$v111$$x1460-2105$$y2019
000141313 909CO $$ooai:inrepo02.dkfz.de:141313$$pVDB
000141313 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6e02c183f41e45a5867dec393fb4616a$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000141313 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7d7ee36ed0313bbc4c91bc3df5950107$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000141313 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000141313 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c2a1ea8cce3580fe2d1c1df120a92b9$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000141313 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000141313 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000141313 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000141313 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000141313 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000141313 9141_ $$y2019
000141313 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000141313 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJNCI-J NATL CANCER I : 2017
000141313 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141313 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141313 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141313 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000141313 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000141313 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000141313 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141313 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141313 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141313 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141313 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141313 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000141313 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141313 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJNCI-J NATL CANCER I : 2017
000141313 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000141313 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x1
000141313 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000141313 9201_ $$0I:(DE-He78)L501-20160331$$kL501$$lDKTK Frankfurt$$x3
000141313 980__ $$ajournal
000141313 980__ $$aVDB
000141313 980__ $$aI:(DE-He78)C070-20160331
000141313 980__ $$aI:(DE-He78)C020-20160331
000141313 980__ $$aI:(DE-He78)L101-20160331
000141313 980__ $$aI:(DE-He78)L501-20160331
000141313 980__ $$aUNRESTRICTED